Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.

Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S.

Cancer Res. 2014 Apr 15;74(8):2160-70. doi: 10.1158/0008-5472.CAN-13-3392. Erratum in: Cancer Res. 2014 Jun 1;74(11):3196.

2.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

3.

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.

Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M.

Breast Cancer Res. 2016 Dec 19;18(1):129.

4.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

5.

Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N.

N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.

6.

Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients.

Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S.

Oncol Rep. 2016 Oct;36(4):2225-35. doi: 10.3892/or.2016.5004. Epub 2016 Aug 4.

PMID:
27499429
7.

Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.

Shan M, Yin H, Li J, Li X, Wang D, Su Y, Niu M, Zhong Z, Wang J, Zhang X, Kang W, Pang D.

Oncotarget. 2016 Apr 5;7(14):18485-94. doi: 10.18632/oncotarget.7608.

8.

Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.

Kristiansen S, Jørgensen LM, Hansen MH, Nielsen D, Sölétormos G.

Biomed Res Int. 2015;2015:986024. doi: 10.1155/2015/986024. Epub 2015 Aug 3.

9.

Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.

Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, Dalay N, Santella RM.

Anticancer Res. 2010 Jul;30(7):2489-96.

10.

CST6 promoter methylation in circulating cell-free DNA of breast cancer patients.

Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V, Lianidou E.

Clin Biochem. 2013 Feb;46(3):235-40. doi: 10.1016/j.clinbiochem.2012.09.015. Epub 2012 Sep 21.

PMID:
23006792
11.

Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.

Kristiansen S, Nielsen D, Sölétormos G.

Clin Epigenetics. 2016 Apr 1;8:35. doi: 10.1186/s13148-016-0199-0. eCollection 2016.

12.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR.

Breast Cancer Res. 2014 Aug 9;16(4):421. doi: 10.1186/s13058-014-0421-y.

13.

Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.

Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Feb;132(1):165-73. doi: 10.1007/s10549-011-1575-2. Epub 2011 May 19.

PMID:
21594664
14.

Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.

Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D.

J Clin Oncol. 2006 Sep 10;24(26):4262-9. Epub 2006 Aug 14.

PMID:
16908936
15.

[Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].

Zhang JJ, Ouyang T, Wan WH, Xu GW, Deng GR.

Ai Zheng. 2007 Jan;26(1):44-7. Chinese.

PMID:
17222366
16.

Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients.

Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Morimoto K, Tamaki Y, Noguchi S.

Oncology. 2012;83(5):273-82. doi: 10.1159/000342083. Epub 2012 Sep 5.

PMID:
22964822
17.

Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.

Matuschek C, Bölke E, Lammering G, Gerber PA, Peiper M, Budach W, Taskin H, Prisack HB, Schieren G, Orth K, Bojar H.

Eur J Med Res. 2010;15:277-86.

18.

Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.

Li Z, Guo X, Tang L, Peng L, Chen M, Luo X, Wang S, Xiao Z, Deng Z, Dai L, Xia K, Wang J.

Tumour Biol. 2016 Oct;37(10):13111-13119. Epub 2016 Jul 23.

PMID:
27449045
19.

[Detection of free tumor-related DNA in the serum of breast cancer patients].

Zhang JJ, Ouyang T, Wan WH, Deng GR.

Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):609-13. Chinese.

PMID:
18210882
20.

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients.

Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2009 Apr 21;100(8):1277-86. doi: 10.1038/sj.bjc.6605013.

Supplemental Content

Support Center